Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Diagnostics is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD,
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
Two commercialization strategy workshops for entrepreneurs and university researchers have been scheduled for the University of Arkansas for Medical Sciences in April.
The Walmart Foundation donated $1.5 million to the Amazeum, the interactive museum scheduled to open in 2015 in Bentonville. The money donated will allow the museum to have a temporary gallery, Amazeum officials said.
In December, Acumen Brands of Fayetteville announced objectives for 2014 that one company executive called “insane.” The leadership wanted five new programs to keep the company vibrant and growing, among those programs “flash sales” and “Marketplace.”
In its third year, Made By Few is a tech conference for designers, developers and entrepreneurs who design and create web and mobile applications. It drew attendees from 15 states to its 2013 version held at the Clinton Presidential Center.